The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).
 
Kim Koczka
No Relationships to Disclose
 
James Vanhie
No Relationships to Disclose
 
Andrea Ibrahim
No Relationships to Disclose
 
Nedal Bukhari
No Relationships to Disclose
 
M. Neil Reaume
Honoraria - Bayer; Ferring; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Pfizer
 
Sandeep R. Sehdev
No Relationships to Disclose
 
Kylea R. Potvin
No Relationships to Disclose
 
Lori Sax
No Relationships to Disclose
 
D. Scott Ernst
No Relationships to Disclose
 
Michael M. Vickers
No Relationships to Disclose
 
Christina M. Canil
No Relationships to Disclose
 
Eric Winquist
Honoraria - Merck
Research Funding - AstraZeneca/MedImmune (Inst); Exelixis (Inst); Medivation (Inst); Oncogenex (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Michael Ong
Honoraria - Astellas Oncology; AstraZeneca; EMD Serono; Janssen; Merck; Roche; Sanofi
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; EMD Serono; Janssen; Merck; Roche; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen